241 related articles for article (PubMed ID: 31490820)
1. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.
Takeshita S; Tanaka KA; Sawa T; Sanda M; Mizobe T; Ogawa S
Anesth Analg; 2020 Feb; 130(2):535-541. PubMed ID: 31490820
[TBL] [Abstract][Full Text] [Related]
2. Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger.
Taune V; Skeppholm M; Ågren A; Gryfelt G; Malmström RE; Wikman A; Van Ryn J; Wallén H
J Thromb Haemost; 2018 Dec; 16(12):2462-2470. PubMed ID: 30288934
[TBL] [Abstract][Full Text] [Related]
3. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
[TBL] [Abstract][Full Text] [Related]
5. Idarucizumab for dabigatran overdose.
Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
[TBL] [Abstract][Full Text] [Related]
6. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
Pollack CV
Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
[TBL] [Abstract][Full Text] [Related]
7. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
Jacquemin M; Toelen J; Schoeters J; van Horenbeeck I; Vanlinthout I; Debasse M; Peetermans M; Vanassche T; Peerlinck K; van Ryn J; Verhamme P
J Thromb Haemost; 2015 Nov; 13(11):2087-92. PubMed ID: 26347330
[TBL] [Abstract][Full Text] [Related]
8. Assessment of patients post reversal with idarucizumab.
Raco V; Ahuja T; Green D
J Thromb Thrombolysis; 2018 Nov; 46(4):466-472. PubMed ID: 30120649
[TBL] [Abstract][Full Text] [Related]
9. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
[TBL] [Abstract][Full Text] [Related]
10. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
[TBL] [Abstract][Full Text] [Related]
12. Incomplete dabigatran reversal with idarucizumab.
Steele AP; Lee JA; Dager WE
Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
[TBL] [Abstract][Full Text] [Related]
13. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.
Taune V; Wallén H; Ågren A; Gryfelt G; Sjövik C; Wintler AM; Malmström RE; Wikman A; Skeppholm M
Thromb Res; 2017 May; 153():76-82. PubMed ID: 28347811
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
15. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
[TBL] [Abstract][Full Text] [Related]
16. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
17. Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.
Grottke O; van Ryn J; Zentai C; Gan G; Honickel M; Rossaint R; Ten Cate H; Spronk HMH
PLoS One; 2019; 14(1):e0209350. PubMed ID: 30615630
[TBL] [Abstract][Full Text] [Related]
18. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
[TBL] [Abstract][Full Text] [Related]
19. The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation.
Bloemen S; Zwaveling S; Douxfils J; Roest M; Kremers R; Mullier F
Thromb Res; 2018 Nov; 171():160-166. PubMed ID: 30316961
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis.
Arellano-Rodrigo E; Fernandez-Gallego V; López-Vilchez I; Molina P; Díaz-Ricart M; Zafar MU; Badimon JJ; van Ryn J; Escolar G
Transfusion; 2019 Jul; 59(7):2436-2445. PubMed ID: 30946491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
